GlassScriptPhysician profile
Bradley Jg Larson
NPI 1194729582
$4,367.68
in general payments reported to CMS, 2019-2025
50 companies · $937 in 2025
The $937 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,269 · 2020: $379 · 2021: $174 · 2022: $361 · 2023: $774 · 2024: $473 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951 · Education: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,950.59 |
| Education | $233.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $489.75 | 2019-2025 | |
| Janssen Biotech, INC. | $438.58 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $343.89 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Novartis Pharmaceuticals Corporation | $270.43 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $204.65 | 2019-2025 | Keytruda |
| Daiichi Sankyo INC. | $196.70 | 2019-2025 | Enhertu, Injectafer |
| Amgen INC. | $185.57 | 2019-2023 | Lumakras |
| Bayer Healthcare Pharmaceuticals INC. | $177.18 | 2019-2025 | |
| Abbvie INC. | $124.99 | 2025 | |
| Incyte Corporation | $122.75 | 2019-2023 | Jakafi |
| Celgene Corporation | $120.61 | 2019-2022 | |
| Genzyme Corporation | $120.44 | 2019-2025 | |
| Genentech USA, INC. | $118.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $110.31 | 2019-2025 | Lynparza |
| Gilead Sciences, INC. | $94.71 | 2019-2025 | Trodelvy |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.